Physician profile
Joanna Edwards
NPI 1558791434
$3,870.30
in general payments reported to CMS, 2019-2025
23 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.09 · 2022: $283 · 2023: $1,002 · 2024: $1,137 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556 · Education: $3.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.99 |
| Education | $3.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.88 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $366.32 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $350.99 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $297.19 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $184.71 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $157.76 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $144.60 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $140.92 | 2023-2025 | Auvelity |
| Pfizer INC. | $140.46 | 2024-2025 | |
| Novo Nordisk INC | $135.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $122.47 | 2019-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.74 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $88.40 | 2024-2025 | Cobenfy |
| Exact Sciences Corporation | $82.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $68.88 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.42 | 2022-2024 | Jardiance, Synjardy |
| Bausch Health US, LLC | $54.84 | 2025 | Aplenzin, Wellbutrin |
| Abbott Laboratories | $39.09 | 2024-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $33.30 | 2019-2025 | Airsupra |
| Hologic Sales and Service, LLC | $22.95 | 2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $20.31 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $16.60 | 2023 | Contrave, Onzetra Xsail |
| Amgen INC. | $13.69 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.